Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
On February 1, 2006, Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("the GSK Trust"), transferred 7,350 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The Company was advised of these transactions on February 2, 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The transaction is noted as being in accordance with Disclosure Rule 3.1.4R(1)(b). The GSK Trust is a discretionary trust where all current and former employees are potential beneficiaries. Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the shares held by the GSK Trust in the same capacity as other employees.
Investor Verification Checklist
- Verify the total number of shares transferred (7,350) and the specific plan involved (SmithKline Beecham Employee Share Option Plan 1991).
- Confirm the date of the transaction (February 1, 2006) versus the date of notification to the Company (February 2, 2006).
- Review the status of the GSK Trust as a discretionary trust for employees and former employees.
- Identify the specific directors with interests in the trust shares: Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop.